Navigation Links
Tepha Partner Launches Novel Monofilament Absorbable Suture Utilizing Tepha's Proprietary Biomaterial
Date:5/1/2009

Tepha Corporate Partner, Aesculap AG, Introduces MonoMax(R) Monofilament Suture at the German Surgical Congress in Munich following Receipt of CE Mark

LEXINGTON, Mass., May 1 /PRNewswire/ -- Tepha, Inc., a developer of medical devices announced today that its corporate partner, Aesculap AG, has received a CE Mark and is launching its MonoMax monofilament absorbable suture for general surgical indications in Europe. The product is made with TephaFLEX(R) fiber, one of Tepha's new class of novel resorbable polyhydroxyalkanoate (PHA) polymers. The Tepha PHA polymer family is a product of the Company's patented recombinant DNA technology, which allows the engineering of resorbable medical devices with mechanical and biologic properties that are matched to specific tissue repair and replacement applications. MonoMax monofilament suture has longer strength retention than currently marketed resorbable sutures, and is more flexible. The product joins a strong portfolio of suture products from B. Braun Aesculap, currently at number two in share of the European suture market.

Miguel Pablo, Vice President Marketing & Sales and Regulatory Affairs Closure Technologies for the Aesculap Division stated, "B. Braun Aesculap is excited to be introducing this new technology into the European market for wound closure. We have been working with Tepha for several years to develop the MonoMax product line and believe Tepha's unique biomaterial will provide benefits to our customers and to their patients".

A clinical trial, the Multi-Center Study to Evaluate the Safety and Efficacy of Aesculap MonoMax for Abdominal Wall Closure or (ISSAAC), was recently concluded with positive results. The trial enrolled approximately 150 patients who were followed for twelve months after surgery. In the trial, the MonoMax suture was used for a continuous all-layer (except skin) suture to close abdominal wall after midline incisions. The primary objective of the trial was to demonstrate that the frequency of wound infection and the frequency of reoperation due to burst-abdomen after primary median laparotomy for elective surgical intervention are equal or lower than in previously reported clinical trials.

Dr. Simon Williams, President and CEO of Tepha, commented, "We are pleased to witness the launch of the MonoMax product and look forward to continued collaboration with our partner Aesculap on additional products based on our TephaFLEX technology".

About Aesculap AG

Aesculap, a Tepha corporate partner since 2004, introduced the MonoMax product to customers at a symposium held in conjunction with the German Surgical Congress in Munich and will be commercializing the product in Europe commencing with Germany immediately following the congress. Based in Germany and Spain, Aesculap is a division of B. Braun Melsungen AG, focused on products for core processes in operative medicine. Aesculap's product range includes sutures, implants for orthopedic and spinal surgery, surgical instruments, endoscopes, surgical motor systems, container and storage systems, and vascular therapy products.

About Tepha, Inc.

Tepha, Inc, is a developer of medical devices derived from a new class of resorbable polymers that have been engineered utilizing recombinant DNA technology. The unique biologic and mechanical properties of the Tepha PHA polymers has been recognized by an expanding list of corporate partners that now includes Aesculap AG, ENTrigue Surgical, HemCon Medical Technologies, NMT Medical (Nasdaq: NMTI), and Tornier, Inc. Tepha received its first FDA 510(k) clearance for its TephaFLEX(R) Absorbable Suture in February, 2007 and the Company and its partners have now received six 510(k)'s covering a range of medical devices including sutures, meshes, and films.

For further information about Tepha, please contact John Hartnett., COO and EVP, at Tepha, Inc., 99 Hayden Ave, Lexington, MA 02421, tel: 781-357-1700. Email: contact@tepha.com. Or visit: http://www.tepha.com

For further information about B. Braun Aesculap, please contact Miguel Pablo, Vice President Marketing & Sales and Regulatory Affairs, Closure Technologies at B. Braun Surgical S.A., Carretera de Terrassa, 121, 08191 Rubi, Barcelona, Spain, tel: +34 93 586 6231. Email: closuretechnologies@bbraun.com. Or visit: www.bbraun.com


'/>"/>
SOURCE Tepha, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dr Stephan Rietiker Joins BioCeramic Therapeutics
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
5. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
6. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
7. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
8. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
9. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
10. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
11. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today announced ... allow more customers to receive their primers in a ... compromise in quality found with other providers. Express oligos ... States at no additional fee. ... genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, and ...
(Date:1/13/2017)... 13, 2017 Research and Markets has announced the ... offering. ... market to grow at a CAGR of 16.83% during the period 2017-2021. ... prospects of the global biopolymers market for 2017-2021. To calculate the market ... of biopolymer products. The report also includes a a discussion of the ...
(Date:1/12/2017)... , ... January 12, 2017 ... ... VTI’S INTERFUSE® IS A SUCCESS , VTI, Vertebral Technologies, Inc., announces the ... InterFuse® laterally expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) has ...
(Date:1/12/2017)... ... January 12, 2017 , ... After her ... Rosendahl’s doctors gave her only a few months to live. Now a paper ... has stabilized Rosendahl’s disease and increased both the quantity and quality of her ...
Breaking Biology Technology:
(Date:1/6/2017)... Colo. , Jan. 5, 2017  SomaLogic ... the "Digital Life Alliance" established by iCarbonX, the ... 2015 to build a "Global Digital Health Ecosystem ... on a combination of individual,s biological, behavioral and ... the agreement between the companies, SomaLogic will provide ...
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at this ... leader in connected health and biometric measurement devices and services, will be ... On display in A&D Medical,s special CES Exhibit Suite , ... ongoing expansion of the company,s WellnessConnected product platform.  ... ...
(Date:1/3/2017)... LAS VEGAS , Jan. 3, 2017 ... announced the introduction of Onitor Track, an innovative biometric ... and men, showcasing this month at the 2017 Consumer ... . In the U.S., the World ... affect more than two-thirds of adults who are overweight ...
Breaking Biology News(10 mins):